|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu YC, Wang HX, Tang L, Ma Y and Zhang FC:
A systematic review of vinorelbine for the treatment of breast
cancer. Breast J. 19:180–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gregory RK and Smith IE: Vinorelbine - a
clinical review. Br J Cancer. 82:1907–1913. 2000.PubMed/NCBI
|
|
4
|
Calcagno AM, Fostel JM, To KK, Salcido CD,
Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ,
et al: Single-step doxorubicin-selected cancer cells overexpress
the ABCG2 drug transporter through epigenetic changes. Br J Cancer.
98:1515–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang JX, Luo Y, Qiu HM and Tang WX:
Characterization and resistance mechanisms of cisplatin-resistant
human hepatocellular carcinoma cell line. Saudi Med J. 30:35–40.
2009.PubMed/NCBI
|
|
6
|
Zhou Y, Ling XL, Li SW, Li XQ and Yan B:
Establishment of a human hepatoma multidrug resistant cell line in
vitro. World J Gastroenterol. 16:2291–2297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li L, Luan Y, Wang G, Tang B, Li D, Zhang
W, Li X, Zhao J, Ding H, Reed E, et al: Development and
characterization of five cell models for chemoresistance studies of
human ovarian carcinoma. Int J Mol Med. 14:257–264. 2004.PubMed/NCBI
|
|
8
|
Shin KH, Ku JL, Kim WH, Lee SE, Lee C, Kim
SW and Park JG: Establishment and characterization of seven human
renal cell carcinoma cell lines. BJU Int. 85:130–138. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han T, Zhu X, Wang J, Zhao H, Ma Q, Zhao
J, Qiu X and Fan Q: Establishment and characterization of a
cisplatin-resistant human osteosarcoma cell line. Oncol Rep.
32:1133–1139. 2014.PubMed/NCBI
|
|
10
|
Felipe AV, Moraes AA, de Oliveira J, da
Silva TD and Forones NM: Establishment and partial characterization
of an epirubicin-resistant gastric cancer cell line with
upregulated ABCB1. Asian Pac J Cancer Prev. 15:6849–6853. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watson MB, Lind MJ and Cawkwell L:
Establishment of in-vitro models of chemotherapy resistance.
Anticancer Drugs. 18:749–754. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang LY and Trujillo JM: Biological
characterization of multi-drug-resistant human colon carcinoma
sublines induced/selected by two methods. Cancer Res. 50:3218–3225.
1990.PubMed/NCBI
|
|
13
|
Ellis GK, Barlow WE, Gralow JR, Hortobagyi
GN, Russell CA, Royce ME, Perez EA, Lew D and Livingston RB: Phase
III comparison of standard doxorubicin and cyclophosphamide versus
weekly doxorubicin and daily oral cyclophosphamide plus granulocyte
colony-stimulating factor as neoadjuvant therapy for inflammatory
and locally advanced breast cancer: SWOG 0012. J Clin Oncol.
29:1014–1021. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pagliaro LC, Williams DL, Daliani D,
Williams MB, Osai W, Kincaid M, Wen S, Thall PF and Pettaway CA:
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for
metastatic penile cancer: A phase II study. J Clin Oncol.
28:3851–3857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Heideman L, Chung CS, Pelling JC,
Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth
inhibition by apigenin in human colon carcinoma cell lines. Mol
Carcinog. 28:102–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Foldbjerg R, Olesen P, Hougaard M, Dang
DA, Hoffmann HJ and Autrup H: PVP-coated silver nanoparticles and
silver ions induce reactive oxygen species, apoptosis and necrosis
in THP-1 monocytes. Toxicol Lett. 190:156–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang D, Sui M, Zhong W, Huang Y and Fan
W: Different admin-istration strategies with paclitaxel induce
distinct phenotypes of multidrug resistance in breast cancer cells.
Cancer Lett. 335:404–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Twentyman PR, Fox NE, Wright KA and
Bleehen NM: Derivation and preliminary characterisation of
adriamycin resistant lines of human lung cancer cells. Br J Cancer.
53:529–537. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu DS, Ma CP and Chang SY: Establishment
and characterization of renal cell carcinoma cell lines with
multidrug resistance. Urol Res. 28:86–92. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hour TC, Chen J, Huang CY, Guan JY, Lu SH,
Hsieh CY and Pu YS: Characterization of chemoresistance mechanisms
in a series of cisplatin-resistant transitional carcinoma cell
lines. Anticancer Res. 20:3221–3225. 2000.PubMed/NCBI
|
|
23
|
Uchiyama-Kokubu N and Watanabe T:
Establishment and characterization of adriamycin-resistant human
colorectal adenocarcinoma HCT-15 cell lines with multidrug
resistance. Anticancer Drugs. 12:769–779. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chung YM, Park S, Park JK, Kim Y, Kang Y
and Yoo YD: Establishment and characterization of
5-fluorouracil-resistant gastric cancer cells. Cancer Lett.
159:95–101. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abrahamova J, Wagnerova M, Kubala E, Malec
V, Simova E, Sirakova I, Pavlikova E, Machova D, Kocak I, Pavlikova
I, et al: Vinorelbine, epirubicin, and methotrexate (VEM) as
primary treatment in locally advanced breast cancer. Oncologist.
6:347–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elomaa I, Joensuu H and Blomqvist C:
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line
therapy in metastatic breast cancer: A randomized phase II trial.
Ann Oncol. 14:699–703. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramanyan S, Abeloff MD, Bond SE,
Davidson NE, Fetting JH, Gordon GB and Kennedy MJ: A phase I/II
study of vinorelbine, doxorubicin, and methotrexate with leucovorin
rescue as first-line treatment for metastatic breast cancer. Cancer
Chemother Pharmacol. 43:497–502. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Richter M, Molnár J and Hilgeroth A:
Biological evaluation of bishydroxymethyl-substituted cage dimeric
1,4-dihydropyridines as a novel class of P-glycoprotein modulating
agents in cancer cells. J Med Chem. 49:2838–2840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cordon-Cardo C, O'Brien JP, Boccia J,
Casals D, Bertino JR and Melamed MR: Expression of the multidrug
resistance gene product (P-glycoprotein) in human normal and tumor
tissues. J Histochem Cytochem. 38:1277–1287. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ardavanis A, Tryfonopoulos D, Orphanos G,
Ioannidis G, Karamouzis M and Rigatos G: First-line chemotherapy
with fluorouracil-epirubicin-navelbine (FEN) combination in
advanced breast cancer. Anticancer Res. 25:4493–4498.
2005.PubMed/NCBI
|
|
31
|
Wang J, Xu B, Yuan P, Ma F and Li Q, Zhang
P, Cai R, Fan Y, Luo Y and Li Q: Capecitabine combined with
docetaxel versus vinorelbine followed by capecitabine maintenance
medication for first-line treatment of patients with advanced
breast cancer: Phase 3 randomized trial. Cancer. 121:3412–3421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stravodimou A, Zaman K and Voutsadakis IA:
Vinorelbine with or without trastuzumab in metastatic breast
cancer: A retrospective single institution series. ISRN Oncol.
2014:2898362014.PubMed/NCBI
|
|
33
|
Breier A, Barancík M, Sulová Z and Uhrík
B: P-glycoprotein - implications of metabolism of neoplastic cells
and cancer therapy. Curr Cancer Drug Targets. 5:457–468. 2005.
View Article : Google Scholar : PubMed/NCBI
|
